Date: 2011-05-25
Type of information:
phase: 1
Announcement: initiation
Company: Isconova (Sweden)
Product: influenza vaccine using Isconova’s adjuvant product Matrix M™
Action mechanism:
Disease: seasonal influenza
Therapeutic area: Infectious diseases
Country:
Trial
details: During 2009, a clinical Phase I vaccination study against avian influenza, was performed through the Panfluvac project. This study was a major milestone achievement for Isconova as it was the first time Isconova’s adjuvant product Matrix M™ was tested in humans. The study results fulfilled all efficacy criteria and based on the positive results a study with a vaccine against seasonal influenza has now been initiated. The new study, carried out by Isconova, will investigate safety as well as examine whether Matrix M™ improves the effect on elderly people, a patient group that, due to a weakened immune system, often does not get sufficient protection with current marketed seasonal influenza vaccines.
Latest
news: Isconova moves forward with the clinical Phase I study of seasonal influenza by initiating vaccinations of the first study participants. A total of 110 healthy volunteers will take part in the study, scheduled to be reported during the first quarter of 2012. The study is a result of Isconova’s increased focus on human vaccines.
